Novo Nordisk completes second and final phase 3a trial with liraglutide as adjunct therapy to insulin for people with type 1 diabetes (NN9211) Bagsværd, Denmark, 24 August 2015 - Novo Nordisk today ...
Please provide your email address to receive an email when new articles are posted on . To assess treatment preferences, Pettus and colleagues sent a survey and received responses from 1,313 adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback